乳腺癌COX-2和MMP-2的表达与新辅助化疗的关系

目的研究COX-2、MMP-2在乳腺癌新辅助化疗前后的表达变化,及其与新辅助化疗疗效的关系。方法应用免疫组织化学法检测48例乳腺癌新辅助化疗前后标本中COX-2、MMP-2的表达。结果新辅助化疗有效率为70.8%。化疗前后COX-2表达变化显著,由化疗前的62.5%降到化疗后的41.7%,(P<0.05);MMP-2表达无明显变化。化疗前后COX-2表达与MMP-2正相关,(P<0.05)。新辅助化疗前COX-2表达阳性者,化疗效果差(P<0.05),MMP-2表达与化疗疗效无关,(P>0.05)。结论COX-2可作为指导乳腺癌化疗并预测化疗敏感性的分子生物学指标,而MMP-2尚不能预测化疗疗效。

Expression of COX-2 and MMP-2 in breast cancer and its relation to neoadjuvant chemotherapy

Objective To observe the change of COX-2 and MMP-2 expression after neoadjuvant chemotherapy(NACT) in breast cancer and its correlation with the clinical response to NACT.Method COX-2 and MMP-2 were examined by immunohistochemical staining in 48 breast cancer samples.Results The overall response rate to neoadjuvant chemotherapy was 70.8%.The expression of COX-2 after neoadjuvant chemotherapy was 41.7%,which was significantly lower than 62.5% before neoadjuvant chemotherapy,P<0.05.MMP-2 expression had no significant change.COX-2 had positive correlation with MMP-2 before and after NACT.The efficacy of NACT had a significantly negative correlation with COX-2 expression,but had no correlation with MMP-2.Conclusions The expression of COX-2 as a molecular marker could guide chemotherapy and predict the response to it in breast cancer,but MMP-2 could not predict the response to chemotherapy.